A selective ALK inhibitor in ALK-rearranged patients
Journal
The Lancet Oncology
Journal Volume
14
Journal Issue
7
Pages
564-565
Date Issued
2013
Author(s)
SDGs
Other Subjects
ch 5424802; crizotinib; docetaxel; pemetrexed; protein tyrosine kinase inhibitor; unclassified drug; ALK gene; brain metastasis; cancer resistance; chemotherapy induced emesis; drug dose escalation; edema; EML4 ALK oncogene; gene; gene amplification; gene mutation; gene rearrangement; gene translocation; human; letter; lung non small cell cancer; optimal drug dose; priority journal; progression free survival; visual disorder; Adenocarcinoma; Carbazoles; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gene Rearrangement; Humans; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases
Type
letter